NCT07510386|Not Yet RecruitingFDA Device
CGM After Discharge From Hospital
Continuous Glucose Monitoring for Post-discharge Diabetes Management
Loading search results
Continuous Glucose Monitoring for Post-discharge Diabetes Management
Sponsor study identifier
interventional
64
1 country
1
Study Start
September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 30, 2026
Actual (reported)April 3, 2026
Actual (reported)September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
time in range 70-180 mg/dl
percent time in range for last 10 days of study
Day 20-30
30 day time in range
Day 30
Percent time >180mg/dL
Day 30
Percent time >250mg/dL
Day 30
Percent time <70mg/dL
Day 30
Percent time <54mg/dL
Day 30
use of unmasked continuous glucose monitoring
Self-monitoring blood glucose (SMBG)+masked CGM
Use of unmasked CGM after discharge
Masked CGM
Icahn School of Medicine at Mount Sinai
New York, New York, 10035, United States
Grenye O'Malley, MD
Icahn School of Medicine at Mount Sinai
First Submitted
March 30, 2026
First Posted
April 3, 2026
Study Start
September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Self-monitoring blood glucose
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 10, 2026
Record last verified: 2026-08
Dates tied to admission which is identifying
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: